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BPAbstract In this study we examine the possibility of constructing metadata from Positron Emis-
sion Tomography images based on a Radial Basis Function neural network, which uses histological
data extracted via the enzyme-linked immunosorbent assay abbreviation. The aim of constructing
such metadata is to achieve a bringing between the binding potential receptor in vitro and in vivo
Positron Emission Tomography procedures, which it is possible to calculate using a classic simpli-
fied reference tissue model. This knowledge representation procedure may then be transmitted in
the Positron Emission Tomography using the testing neural network procedure. The latest satisfies
the primary aim of this study, which was to avoid painful and risky biopsies of patients.
 2016 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Biopsy for histological assessment is an important tool in the
diagnosis and management of cancer. This traditional method
helps resolve and characterize the stage of the disease by giving
a straight therapeutic line in patients with tumor tissue. But
this method also has a low possibility of seeding tumor cells.
Indeed, research suggests that after diagnostic biopsies of
tumors, many patients developed cancer [1].Numerous clinical studies have related the connection
between tumor tissue and angiogenesis. Meanwhile, there is a
correlation between an increased number of new vessels and
the progress of metastasis. Recently, researchers have exten-
sively studied this mechanism, because it is widely believed that
pre-cancerous tissues acquire angiogenic capacities on their
way to becoming dangerous. Among various regulators of
angiogenesis, researchers believe that a vascular endothelial
growth factor (VEGF) plays a pivotal role in augmenting all
steps of angiogenesis [2,3].
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the overexpression of the VEGF. The VEGF supplies more
oxygen and nutrients, which results in dramatic changes in
the molecular mechanism of cancer. At this point, VEGF dis-
crimination and detection in blood in low concentrations could
be a high-priority research parameter, which would create an
innovative tool in the field of data mining systems; this topic
has not been explored [1]. One popular method of assaying
VEGF is the enzyme-linked immunosorbent assay (ELISA).
ELISA is a popular ‘‘wet-lab”-type analytic biochemistry
assay that uses a solid-phase enzyme immunoassay (EIA) to
detect the presence of a substance, usually an antigen, in a liq-
uid sample or wet sample [2]. VEGF is an antigen consisting of
dimeric glycoproteine, which consists of a significant parame-
ter during physiological and pathological angiogenesis [3].
It induces germinating angiogenesis, improves vessel per-
meability, and controls vasculature restructuring and several
pathologies [4,5]. It is produced in arteries, veins, and lym-
phatic tissues, where its role is to restore oxygen supply to tis-
sues when blood circulation is inadequate. Hypoxia stimulates
the expression of the VEGF protein [6–9].
The overexpression of VEGF is an index for cell abnormal-
ities, diseases, and several intraocular symptoms. In vitro stud-
ies have shown that pathological angiogenesis [6,7] and
neovascular disorders cause the growth and migration of cells
[10,11]. An increased concentration of VEGF is correlated
with poor patient survival, reduced cell function, and early-
stage metastasis. Thus, this dimeric protein provides a useful
marker and is a measurable element of tumor biology.
Only a few studies treat the quantification of the VEGF
protein, but ELISA forms the basis of one of the most com-
mon techniques used in this type of research [4,12,13]. Studies
have shown that the quantification of VEGF and other angio-
genic peptides in tissue, together with measurement of neovas-
cularization in the tumor itself, may be used to increase the
accuracy of prognosis for patients with brain tumors [4]. The
concentration of VEGF in healthy and brain-cancer patients
was observed by directly measuring VEGF using ELISA. ThisFigure 1 A typical series of clinical routines anresearch revealed significantly elevated levels in the tissue and
cyst fluid of glioblastomas, suggesting that VEGF is a measur-
able parameter of brain tumor biology [4].
The in vivo procedure, Positron Emission Tomography
(PET), is a very sensitive quantitative method used to describe
tissue penetration. PET has been widely used in clinical oncol-
ogy for tumor staging and for measuring tumor glucose meta-
bolism. PET indirectly measures VEGF by using the
concentrations of tracers such as an 89Zr-labeled tracer [14].
Fig. 1 depicts the usual procedure for verifying a cancer diag-
nosis via clinical routines and research studies.
The clinical routine is divided into two procedures: in vivo
(MRI and PET scans) and in vitro (biopsy and histological
assessment) procedures. The penultimate procedure consists
of correlating the imaging and histology assessments. Some
questions that naturally arise from this procedure are: Is it pos-
sible to avoid the painful and risky biopsies as well as histolog-
ical assessments? In recent years, several studies determined
that the precision of the diagnosis analysis of various applied
data mining classification techniques, as well as the execution
of those techniques, are acceptable to support medical profes-
sionals in making primary diagnoses and avoiding biopsies [4].
Is there any reason the data extracted from histological exam-
inations conducted on some patients could not be applied to
other patients? Is it possible to use data mining to extract
information from biopsies and histological assessments, and
to use these data in conjunction with MRI and PET images?
The present study answers these questions.
In artificial intelligence science, artificial neural networks
(ANNs) consist of a category of statistical learning model that
is based on biological neurons. ANNs train and obtain knowl-
edge from standard data. The training procedure of ANNs suc-
cessfully simulates the functionality of a small biological neural
cluster. Nowadays, medical professionals in several disciplines
apply ANNs for medical diagnosis. The structure of these net-
works consists of hidden notes and weights that connect the
neurons with different types of logic. Thus, there are several
types of ANNs: networks that contain Radial Basis Functiond research studies used in cancer diagnosis.
S16 M. Poulos et al.(RBF) neural networks, feed-forward neural networks (FNNs),
and neural networks that have dynamic properties [15,16]. In
this study, we selected the RBF-type neural network because
this type can change both the number of hidden or competitive
layers and the weights according to the input data vector. We
calculated the final decision nonlinearly, using the weights as
parametric features. This characteristic makes the method ideal
for complex nonlinear dynamic applications. It is reasonable to
suppose that RBF design algorithms with adaptive structures
will reveal better performance for classification of histologic
data according to supervised biopsy decision-making. ‘‘Neural
vector construction using in vivo and in vitro vectors section”
analyzes more details of this procedure.
Here, we examine the possibility of combining histological
and medical imaging techniques for constructing and export-
ing information related to cancer progress, using the above
data-mining concept. The basic pillar of the method links the
in vitro (ELISA) and in vivo (PET scans) experiments on the
basis of a bio-mathematical model that measures both in the
equivalent quantification the VEGF concentration. Fig. 3
depicts the proposed scientific practices for this implementa-
tion; the analyses are as follows:
(i) The formulation of a mathematical model that combines
two equivalent features vectors for in vitro (ELISA
biosensor) and vectors for in vivo (PET) procedures,Figure 2 The flow diagwhich are based on the value calculation of binding
potential (BP) receptor in both cases. This formulation
is achieved using the simplified reference tissue model
[11].
(ii) Training and testing machine procedure, implemented
via an artificial RBF neural network in order to in vivo
procedure the RBF to respond to the question about
the concentration of the intracellular VEGF in the tissue
in the scale (where ‘‘” means not detected, ‘‘+” means
moderate, and ‘‘++” means strong) in which is related
directly with the tumor grade by three degrees of severity
(0 or 1 or 2) [4].
Methods
The deeper target of this procedure focuses on extracting a
suitable vector of VEGF concentration from in vitro experi-
ments by using a formulation in a in vivo PET procedure.
The suitability of this vector is connected with its ability to
train a well-fitted artificial neural network; this suitability is
called ~Phistology. However, the procedure also focuses on calcu-
lating a suitable testing neural network vector that is equiva-
lent to ~Phistology, which is written ~Ppet. The following sections,
as well as Fig. 2, analyze the above-mentioned description.ram of the method.
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PET research conducted with neuroreceptor radioligands
permits the quantification of the distribution and binding of
characteristics [17]. Compartmental modeling with a metabolite-
corrected arterial input function is frequently exploited to strictly
quantify PET neuroreceptor studies based on determination of
the saturation’s receptor. In kinetic theory, the role of the com-
partments is to measure the change between tracer concentrations.
In these studies, binding potential (BP) is a crucial parameter in
the use of Positron Emission Tomography (PET) to measure
the density of ‘‘accessible” receptors. Although BP is robust, con-
vergence rates are slow and the other parameters can have large
standard errors. To solve this problem, we determined a simplified
reference tissue that has only three parameters. For this reason,
we introduced a typical compartmental modeling procedure to
describe the absorption of the tracer in tissue with a three-
compartment model (Fig. 3).
The general kinetic ligand-binding model consists of three
tracer compartments:
(a) compartments in plasma Cp tracer that is free;
(b) non-specifically bound compartments in tissue CFþNs;
and
(c) tracer compartments that are specifically bound in tissue
CSP
Ct and Cr represent the compartments of the tissue and non-
specific binding, respectively (Fig. 2). Fig. 2 includes first-
order rate constants that describe the transport of tracer from
blood to tissue K1 (ml/min/ml), the efflux from tissue to blood
k2 (min
1) [14,18–24]. Furthermore, K 01 is the rate constant
for transfer from plasma to reference compartment
(ml * ml1 * min1), k02 is the rate constant for transfer from ref-
erence to plasma compartment (min1), and t is time (min). Eq. (1)
expresses the exchange between plasma and reference tissue.
dCr ðtÞ=dt ¼ K01Cp ðtÞ  k02CrðtÞ ð1Þ
Additionally, the significant parameter R1 is determined as
the ratio of the constants K1 and K
0
1 (see Eq. (2)), which
accounts for any differences in delivery to the region of interest
and the reference tissue.
R1 ¼ K1=K01 ð2ÞFigure 3 A typical three-compartment model.Eq. (3) introduces the hypothesis that the volume of distri-
bution of the non-specifically-bound tracer in both tissues is
the same completes.
K01=k
0
2 ¼ K1=k2 ð3Þ
The constant k2a (min
1) is the apparent (overall) rate con-
stant for transfer from specific compartment to plasma [14].
Eq. (4) modifies Eq. (1) and represents more simplified tracer
kinetics.
dCtðtÞ=dt ¼ K1CpðtÞ  k2aCtðtÞ ð4Þ
Thereinafter, the total tracer volume of distribution takes
the following expression:
K1=k2a ¼ ðK1=k2Þð1þ BPÞ ð5Þ
Finally, the following expression can be derived from
Eqs. (1)–(5):
CtðtÞ ¼ R1CrðtÞ þ k2  R1k2=ð1þ BPÞf gCrðtÞ
 exp k2tð1þ BPÞf g ð6Þ
According to Eq. (6), the simplified model contains only
three parameters: k2, R1, and BP. These parameters determine
the vector b:
~b ¼
R1
k2
BP
2
64
3
75 ð7Þ
This vector consists of the main research in this study,
because the calculation in the in vivo procedure is highly accu-
rate [14] and constitutes the bridging characteristic between the
in vivo and in vitro conditions.
In accordance with Lammertsma et al. [14], the vector Vvivo
depicts the calculated parameters of the in vivo procedure. The
vector Vvivo is analyzed as follows:
~Vvivo ¼
R1
k2
BP
Ct
Cr
Cp
2
666666666664
3
777777777775
ð8ÞVector formulation in in vitro procedure
The theory for quantification of in vivo neuroreceptor binding
is based on the theory for in vitro binding assays [25], which
involves a radioreceptor-enriched preparation with a radioli-
gand. Where, Radioligand binding assays are a quite simple
but really dominant tool for studying receptors. In biochem-
istry a receptor is a protein molecule that accepts chemical
signals beyond the cell. This theory is based on the law of mass
action, which states that the ligand binds to receptors (associ-
ation) at a rate proportional to the concentration of ligand and
receptors, and that the resultant ligand–receptor complex
breaks down (dissociation) at a rate proportional to the con-
centration of the complex [21,22]. Eq. (9) describes this rate:
d
dt
½RL ¼ kon½R½L  koff½RL ð9Þ
Table 2 Mapping of concentrations between in vivo and
VEGF ELISA procedures.
Concentration in vivo [11] Concentration in vitro [1]
Cf [Serum ELISA]
Ct [Tissue ELISA]
Cb [Tissue ELISA] – [Serum ELISA]
S18 M. Poulos et al.where kon and koff are the rate constants for association and
dissociation, respectively. The concentrations [R], [L], and
[RL] correspond to receptors, ligand complex, and ligand
and receptor–ligand complex, respectively.
The constant KD is the equilibrium dissociation constant
[17]. Its reciprocal value is defined as the affinity of the ligand
for the receptor and it is calculated in Eq. (10).
½R½L
RL
¼ koff
kon
 KD ð10Þ
The total receptor-concentration, Bmax ¼ ½R þ ½RL and
considering that B ¼ ½RL and B½L  BmaxKD  BP [12], then
BP ¼ ½RL½L (see Table 1).
Different symbols are used for in vivo and in vitro proce-
dures. Therefore, if Eqs. (4) and (5) depicted in Eqs. (8)–(10),
then Table 1 presents the following mapping of the compart-
ments’ factors for in vivo and in vitro procedures.
According to the ELISA used to detect the concentration of
VEGF [1], the total VEGF concentration CTBiopsy is estimated
using two non-collinear concentrations: the VEGF concentra-
tion in glioblastoma tissue Ctissue biopsy and the VEGF concen-
tration of the serum Cserum biopsy. Studying the formulation of a
VEGF ELISA in serum and tumor Tissue [4], we constructed a
relationship between the symbols of the in vivo and the VEGF
ELISA procedures, which are depicted in Table 2.
Neural vector construction using in vivo and in vitro vectors
The aim of the above mapping (see Table 2) was to correspond
in vivo concentrations with the concentrations of ELISA pro-
cedure, which are very important in the evaluation of the intra-
cellular VEGF immunostaining using a semiquantitative scale.
Taking into account the in vitro ELISA procedure, we con-
structed a vector:
VElisa ¼
Cf
Ct
 
ð11Þ
The next step was to modify the vector of Eq. (11) in order
to calculate in vivo factors. We used Tables 1 and 2 to achieve
this modification.
This modification is succeeded in the following stages:
VElisa ¼
Cf
Ct
 
¼ ½RL  ½L½RL
 
) Vvivo ¼
½RL  ½L
½RL
 
½L
¼
½RL
½L  1
½RL
½L
2
4
3
5 ¼ BP 1
BP
 
ð12ÞTable 1 The mapping of in vivo into in vitro parameters.
In vivo parameters In vitro parameters
R1 Not estimated
k2 Not estimated
Not estimated [R]
[Cb]-not estimated [L]
[Cf]-not estimated [RL] – [L]
BP ½RL½L
[Ct] [RL]
[Cp] [R][L]
[Cr] Not estimatedWe designed a RBF neural network to classify the intracel-
lular VEGF immunostaining into three classes. The architec-
ture design as well as the learning and testing procedures
occurred according to previous our knowledge [26–30]. In
order to achieve this, we trained, in vitro, vectors of Eq. (11).
In the testing procedure, we used as testing vectors, in vivo,
vectors of Eq. (12). Fig. 4 shows the architecture of the RBF
network used to classify these vectors (model order p= 2).
We weighted and fed input vectors of dimensionality 2  1
to the first layer of neurons, known as the competitive layer.
These neurons compete for inputs in a ‘‘greedy” way, hence
their name. Four such neurons formed the competitive layer
in our case. The output of the competitive layer, which is a
grouping of the inputs into sub-classes, is fed to the second
linear layer, which groups subclasses into target classes. The
weights connecting the two layers take on binary values of zero
or one, indicating mere class membership and not actual
weighting. Three target classes exist here, the class of interest
(A – not detected or B+, moderate or C++, strong).
Experimental part
In the RBF training procedure we constructed according to
Eq. (12) a simulation of 60 modification ELISA vectors. We
generated this simulation from Table 1 of relative study [4].
We determined the following ranges of concentrations in deci-
sion classes (see Table 3) in the specific case of vessel immuno-
histochemistry of glioblastoma. VEGF protein localized to the
cytoplasm of tumor cells and vasculature in gliomas, predom-
inantly in the peripheral microvessel ‘‘hot spots” as well as
around the necrosis in glioblastomas [4].
Thereafter, we calculated the BP factors using ELISA-
simulated data and applied Eq. (12). Table 4 presents these
data.
Training procedure
The next step of this implementation was the training of a well-
fitted RBF neural network by simulated vectors from Table 4.In vitro – ELISA
Not estimated
Not estimated
Not estimated
[Tissue ELISA] – [Serum ELISA]
[Serum ELISA]
Estimated
[Tissue ELISA]
Estimated
Not estimated
Figure 4 The architecture of the RBF neural network.
Table 3 The classification concentrations in grades [1].
One hour after injection Concentration , not detected Concentration +, moderate Concentration ++, strong
Tissue ELISA (Cf) pg/mg Cf < 7300 7300 < Cf < 8000 8000 < Cf < 10,000
Serum ELISA (Ct) pg/ml Ct < 20 20 < Ct < 40 40 < Ct < 100
Normalization
Tissue ELISA (Cf)/max = 10,000 Cf < 0.73 0.73 6 Cf < 0.80 0.80 6 Cf < 1
Serum ELISA (Ct)/max = 100 Ct < 0.2 0.2 6 Ct < 0.4 0.4 6 Ct < 1
Towards a histological depiction in 3D imaging PET S19In this way, we created 30 vectors in each category (for a total
of 90 vectors; see Table 4). In the training procedure we used
15 of each category (class) so that the rest vectors would be
used in the testing procedure. In the training procedure the
goal of the convergence 0.05 was achieved in 67 epochs (see
Fig. 5), with hidden units hj = 18, which we adopted after
experimentation. This implements via the matlab function
net = newrb (P, C, 0.05, 0.1), where P is the training vectors,
C the target classes of each vector, 0.05 is the goal of the con-
vergence, and 0.1 is the spread of the training iteration.
Testing procedure
We implemented this procedure using the rest vectors (15 for
each category) as a test in the weighting net, which is extracted
in the training procedure and is expressed by the following
equation:
fðxÞ ¼
Xm
j¼1
wjhjðxÞ ð13Þ
In the network testing procedure, each candidate testing
vector x was related to the extracted weights of the training
procedure via Eq. (13) and was set to respond within the fol-
lowing thresholds, which we determined using the following
piecewise-linear function.fðxÞ ¼
1! if; þ0:5 < x 6 þ1:5
0! if; 0:5 < x 6 þ0:5
1! if; 1:5 < x 6 0:5
0
BBB@
1
CCCA ð14Þ
Table 5 presents the testing results, as derived from the
decision boundaries of Eq. (14).Evaluation of the results
According to results of the Table 5, we exact the first statistic
evaluation, which focuses on the percentage of true of false
positives and negative identifications. Table 6 presents these
results.
According to the above notation, sensitivity is the propor-
tion of positive cases correctly identified by the test, while
specificity is the proportion of negative cases correctly identi-
fied by the test. For the results of Table 6 these values are
calculated as follows:
Sensitivity ¼ 14þ 13þ 13
45
 89% and
Specificity ¼ 29þ 28þ 28
90
 94%
Table 4 Simulated vectors using the values of Table 3.
, not detected +, moderate ++, strong
BP BP-1 BP BP-1 BP BP-1
1.23 0.23 1.52 0.52 7.00 6.00
0.78 1.78 1.38 0.38 26.67 25.67
2.00 1.00 1.80 0.80 1.98 0.98
1.14 0.14 2.03 1.03 2.31 1.31
1.27 0.27 2.21 1.21 2.73 1.73
3.00 4.00 1.79 0.79 2.59 1.59
4.00 3.00 1.48 0.48 40.00 39.00
2.57 1.57 1.62 0.62 6.54 5.54
3.50 4.50 1.88 0.88 3.92 2.92
1.60 0.60 1.46 0.46 3.79 2.79
1.12 0.12 1.39 0.39 6.31 5.31
1.80 0.80 1.54 0.54 24.25 23.25
1.78 0.78 1.48 0.48 2.58 1.58
1.19 0.19 1.74 0.74 7.58 6.58
1.07 0.07 2.05 1.05 2.44 1.44
1.06 0.06 1.92 0.92 1.83 0.83
5.00 4.00 1.66 0.66 2.41 1.41
1.80 0.80 1.76 0.76 13.83 12.83
1.26 0.26 1.42 0.42 1.88 0.88
0.27 1.27 2.06 1.06 6.60 5.60
1.45 0.45 1.52 0.52 1.83 0.83
1.05 0.05 1.66 0.66 49.00 48.00
3.00 2.00 2.09 1.09 12.50 11.50
1.06 0.06 1.40 0.40 3.84 2.84
1.25 0.25 1.63 0.63 4.37 3.37
0.13 1.13 2.21 1.21 2.00 1.00
1.45 0.45 1.53 0.53 2.41 1.41
1.08 0.08 1.55 0.55 3.31 2.31
1.07 0.07 1.70 0.70 8.90 7.90
1.25 0.25 1.72 0.72 7.27 8.27
Table 5 Testing results of the RBF neural network.
Categories , not detected +, moderate ++, strong
, not detected 14 1 0
+, moderate 1 13 1
++, strong 0 2 13
Total 15 16 14
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Evaluation of the proposed method
In this study, we proposed a data-mining feature extraction
combining experimental data from an in vitro biopsy withFigure 5 The training error procin vivo data. For the data-mining procedure, we used a simpli-
fied compartmental model based on PET tracers. We intro-
duced the possibility of constructing PET images with biopsy
information obtained from the in vivo procedure. For example,
we used the cytoplasm of tumor cells and vasculature in glio-
mas and in vitro electrochemical detection of VEGF as a cancer
biomarker using a fluorescence-based ELISA biosensor. For
this reason we connected in vitro with in vivo Eq. (12) regarding
the the evaluation of the intracellular VEGF immunostaining
using a semiquantitative scale. However, in this stage we used
only ‘‘in vitro” values, which we transformed into BP values
in order to calculate ‘‘in vivo” values in the PET procedure.
In the second stage, we will attempt to train in vitro data via
an RBF neural network, drawing information from the pub-
lished results [4]. From the BP values it is possible to calculate
the in vivo procedure in PET scanning [30]. In particular, BP
values calculated from graphical analysis of dynamic micro-
PET [31,32]. The ultimate goal of this approach is to eliminate
resection surgery in histological procedures by using a data-
mining technique of in vitro histological measurements and
fitting significant histologic information in 3D PET images.
Future plan
We propose that future work (see Fig. 3) should focus on
implementing the process outlined in this study in four stages:
 The first stage will aim to obtain real data from a histolog-
ical laboratory of a hospital that uses the same histological
practice, in order to construct a database linking the cellular
data with degrees of malignancy.edure of RBF neural network.
Table 6 Positive and negative classification scores of RBF neural network.
Categories True positive identification False positive identification True negative identification False negative identification
, not detected 14/15 = 93.33% 1/15 = 0.06% 29/30 = 0.97% 1/30 = 0.03%
+, moderate 13/15 = 0.87% 2/15 = 0.13% 28/30 = 0.93% 2/30 = 0.07%
++, strong 13/15 = 0.87% 2/15 = 0.13% 28/30 = 0.93% 2/30 = 0.07%
Figure 6 The future plan of the proposed method according to Eq. (15).
Towards a histological depiction in 3D imaging PET S21 In the second stage we will adapt these values in a neural
network training procedure based on Eq. (12).
 In the third stage we will obtain an online response from the
neural network based on the questions referred by the PET
scanner. Finally, the fourth stage will consist of the integration of
the neural network’s responses with the DICOM Formats.This stage could be implemented via composed messages
contained within the mean pixel values within the ROI
volume. Given a distinguishable point spread function,
the problem generalizes to three dimensions using a linear
transformation:P  R  xþ e ¼ b ð15Þ
S22 M. Poulos et al.where e 	 Nð0;RÞ, P is the point spread function, R is a matrix
of full column rank containing the region definitions, x is the
true mean regional concentration, e is the noise in the data,
b is the PET data, and R is the covariance matrix of the noise
in the data. In our proposition, the true mean values (x) are
accompanied per pixel by the values 1, 0.5, 0.5, or 1, which
correspond to the grades decisions [33]. Matrix b contains the
information of the neural network decision, which could be
encrypted in DICOM format using the ROI within the ROI
volume. Fig. 6 analyzes depicts this future plan.Overview box:
What do we already know about the subject?
The theory for quantification of in vivo neuroreceptor
binding is based on the theory for in vitro VEGF binding
assays, which involves incubation of a receptor-enriched
preparation with a radioligand. Until now, this theory
has not been associated with the weight of the VEGF con-
centrations in the tissue and sera.
What does your proposed theory add to the current
knowledge available, and what benefits does it have?
The proposed theory focuses on enriching PET images
with in vitro histological information using an artificial
neural network (ANN). The benefit of this study is a dee-
per connection between mathematical algorithms and
chemical biological data. This association could be a sig-
nificant tool in the possible diagnostic relation between
in vitro and in vivo VEGF binding assays. Additionally,
this method could help medical professionals make early
diagnoses of cell abnormalities and eliminate resection
surgery.
Among numerous available studies, what special further
study is proposed for testing the idea?
The method focuses on creating a relationship between
crucial quantifications of VEGF in tissue and sera of his-
tological findings by ELISA with the binding potential,
which is the most important parameter in in vivo neurore-
ceptors. This relationship is achieved with a well-fitted
ANN. The accuracy of this method is certified why in sim-
ilar connections the ANNs showed that in the training
procedure these simulate with the functionality of small
biological neural cluster. Thus, in the testing procedure
with binding potential (BP) of the PET investigation we
expect the verification of the ANN histological decision
with the comparison with in vitro ELISA histological
investigation using the same findings.Conflict of interest
There is no conflict of interest in this study.
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